Kardigan is a clinical-stage precision therapeutics company focused on developing medicines that target the root causes of specific cardiovascular diseases lacking approved treatments. The company aims to develop multiple targeted cardiovascular treatments in parallel, leveraging expertise in cardiovascular biology and advanced analytics to accelerate drug discovery and development. Their management team includes leaders with a proven track record in cardiovascular drug development.
Per S-1 disclosure; % may not sum to 100% when ownership is nested, multi-class, or reported on different bases.
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | Not provided | Not provided |
| Adjusted Net Loss | -$191.9M | -$88.7M |
Based on price range midpoint and most recent fiscal year data.
The company operates in the cardiovascular therapeutics market, which is currently underserved due to a lack of innovative treatments. Kardigan competes with companies like MyoKardia, Inc.
Proceeds from the IPO will be utilized to fund the development of their product candidates and support the necessary activities for commercialization.
No broker information available yet
Check back later for updates
Reported by users or publicly disclosed. Information is for reference only.